Meeting
2022 ASCO Genitourinary Cancers Symposium
A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.
Authors
Waleed Ikram
Mayo Clinic, Phoenix, AZ
Waleed Ikram , Syed Arsalan Ahmed Naqvi , Ezza Fatima , Rabbia Siddiqi , Mahnoor Islam , Noureen Asghar , Kaneez Zahra Rubab Khakwani , Ahsan Masood Khan , Wenxin Xu , Syed A. Hussain , Guru P. Sonpavde , Alan Haruo Bryce , Irbaz Bin Riaz , Parminder Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 518)
DOI
10.1200/JCO.2022.40.6_suppl.518
Abstract #
518
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
First Author: Yongjune Lee
Poster
2023 ASCO Genitourinary Cancers Symposium
Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
First Author: Ahsan Ayaz
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Annual Meeting
Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.
First Author: Waleed Ikram